What Happened?
South San Francisco, California-based Lyell Appointed Julie Urvater as Senior Director, Intellectual Property
About the Company
We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.
About the Person
Julie Urvater is Senior Director, Intellectual Property at Lyell. Previously, Julie held various senior IT leadership roles in the industry.
Info Source
News
Short Profile